Drug Profile
Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences
Alternative Names: B/F/TAF; BIC/FTC/TAF; Bictegravir/F/TAF; Bictegravir/tenofovir-alafenamide/emtricitabine; Biktarvy; Emtricitabine/bictegravir/tenfovir-alafenamide; Emtricitabine/GS 9883/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/GS-9883; Emtricitabine/tenofovir-alafenamine/bictegravir; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide; J05AR20; Tenofovir-alafenamide/bictegravir/emtricitabine; Tenofovir-alafenamide/emtricitabine/bictegravir; Tenofovir-alafenamide/emtricitabine/GS-9883; Tenofovir-alafenamide/GS-9338/emtricitabineLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals; Deoxyribonucleosides; Oxazepines; Purines; Pyrazines; Pyridones; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase I inhibitors; DNA polymerase II inhibitors; HIV integrase inhibitors; HIV reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
- Phase III Hepatitis B
Most Recent Events
- 10 Apr 2024 Atea Pharmaceuticals plans a phase I trial (In volunteers, Monotherapy, Combination therapy) in Canada (NCT06356194)
- 15 Mar 2024 Gilead Sciences completes a phase III trial in Hepatitis B and HIV-1 infections (Treatment-naïve) in USA, Puerto Rico, France, Spain, Greece, China, Dominican Republic, Hong Kong, Japan, South Korea, Malaysia, Singapore, Taiwan, Thailand, Turkey (NCT03547908) (EudraCT2018-000926-79)
- 07 Mar 2024 Updated adverse events data from a phase III Alliance trial in HIV-1 infections and Hepatitis B released by Gilead Sciences